Guiding dose increases in patients incompletely responsive to ususal doses of atomoxetine by determining plasma atomoxetine concentrations: a randomized, double-blind study
Latest Information Update: 20 Jun 2007
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 20 Jun 2007 New trial record.